Development of new adoptive T cell immunotherapy by modification of Nrf2 expression

摘要

The present invention relates to T cell anti-cancer immunotherapy based on the regulation of Nrf2 expression. The T cell anti-cancer immunotherapy targeting Nrf2 according to the present invention is deeply involved in the expression of Nrf2 in the T cell to the T cell anergy, which is one of the main mechanisms by which cancer cells avoid the monitoring of the immune system, so that the tumor cells tolerate T cells (tolerance) can be solved, and by targeting Nrf2, the greatest feature is that the anti-cancer immunotherapy efficacy is increased. The present invention proposes a new T cell anti-cancer immunotherapy method targeting Nrf2 and a next-generation anti-cancer immunotherapy efficacy T cell, grafting it into CAR-T, engineered T cell, TIL T production, and improving therapeutic efficacy in several solid cancers including lymphoma. It can be useful as a new anti-cancer treatment method.